Ignite Creation Date:
2024-05-05 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00415142
Status:
COMPLETED
Last Update Posted:
2016-05-24
First Post:
2006-12-21
Brief Title:
An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily in Elderly Patients With Major Depressive Disorder
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
An Eight-week Multinational Multicenter Randomized Double-blind Placebo-controlled Study With Escitalopram as an Active Control to Evaluate the Efficacy Safety and Tolerability of a Saredutant 100 mg Dose Once Daily in Elderly Patients With Major Depressive Disorder
Status:
COMPLETED
Status Verified Date:
2016-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to evaluate the efficacy of saredutant in the treatment of Major Depressive Disorder in elderly patientsTo evaluate the tolerability safety and efficacy on disability and quality of life in patients with major depressive disorderTo evaluate safety and tolerability of 24 weeks of additional treatment in patients completing the initial 8-week treatment period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None